<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30104114</PMID><DateCompleted><Year>2019</Year><Month>02</Month><Day>07</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>37</Issue><PubDate><Year>2018</Year><Month>Sep</Month><Day>05</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Non-interference of Bovine-Human reassortant pentavalent rotavirus vaccine ROTASIIL&#xae; with the immunogenicity of infant vaccines in comparison with a licensed rotavirus vaccine.</ArticleTitle><Pagination><StartPage>5519</StartPage><EndPage>5523</EndPage><MedlinePgn>5519-5523</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2018.07.064</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(18)31073-9</ELocationID><Abstract><AbstractText Label="BACKGROUND">A newly developed bovine-human reassortant pentavalent vaccine (BRV-PV, ROTASIIL&#xae;) was tested for its potential effect on the immunogenicity of concomitantly administered EPI vaccines in infants in a randomized controlled study in India.</AbstractText><AbstractText Label="METHODS">In this Phase III, multicenter, open label, randomized, controlled study, three doses of BRV-PV or two doses of Rotarix&#xae; and one dose of placebo were given to healthy infants at 6, 10, and 14&#x202f;weeks of age. Subjects also received three doses of DTwP-HepB-Hib (diphtheria, tetanus, whole-cell pertussis, hepatitis B, and haemophilus influenzae type b conjugate - pentavalent vaccine) and oral polio vaccine concomitantly at 6, 10, and 14&#x202f;weeks of age and a single dose of inactivated polio vaccine at 14&#x202f;weeks of age. Blood samples were collected four weeks after the final vaccination to assess immune responses to all the vaccines administered. For diphtheria, tetanus, hepatitis B, Hib, polio type 1, and polio type 3 antibodies, non-interference was to be supported if the lower limit of the two-sided 90% confidence interval (CI) for the seroprotection rate difference for the BRV-PV group minus the Rotarix&#xae; group was &gt;10.0%. For pertussis antibodies, non-interference was to be supported if the lower limit of the two-sided 90% CI for the ratio of geometric mean concentrations (GMCs) was &gt;0.5.</AbstractText><AbstractText Label="RESULTS">A total of 1500 infants were randomized to either BRV-PV (1125 infants) or Rotarix&#xae; (375 infants), of which 1341 completed the study as per the protocol. More than 97% of subjects achieved seroprotective antibody titres against diphtheria, tetanus, hepatitis B, Hib, polio type 1, and polio type 3 in both groups. The difference in seroprotection rates between the BRV-PV group and the Rotarix&#xae; group for all these antibodies was less than 1%. The ratio of GMCs of anti-pertussis IgG concentrations for the BRV-PV group versus Rotarix&#xae; was 1.04 [90% CI: 0.90; 1.19].</AbstractText><AbstractText Label="CONCLUSION">BRV-PV does not interfere with the immunogenicity of concomitantly administered routine infants vaccines.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Desai</LastName><ForeName>Sajjad</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Serum Institute of India Pvt. Ltd., Pune, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rathi</LastName><ForeName>Niraj</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>PATH, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawade</LastName><ForeName>Anand</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Vadu Rural Health Program KEM Hospital Research Centre Vadu, Pune, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Venkatramanan</LastName><ForeName>Padmasani</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Sri Ramachandra Medical Centre, Chennai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kundu</LastName><ForeName>Ritabrata</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Child Health, Kolkata, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lalwani</LastName><ForeName>Sanjay K</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Bharati Vidyapeeth Medical College &amp; Hospital, Pune, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dubey</LastName><ForeName>A P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Maulana Azad Medical College, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Venkateswara Rao</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Gandhi Medical College &amp; Gandhi Hospital, Secunderabad, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Narayanappa</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>JSS Medical College &amp; Hospital, Mysore, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghildiyal</LastName><ForeName>Radha</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>T.N. Medical College &amp; B.Y.L. Nair Charitable Hospital, Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gogtay</LastName><ForeName>Nithya J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Seth GS Medical College &amp; KEM Hospital, Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Venugopal</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Andhra Medical College, Visakhapatnam, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palkar</LastName><ForeName>Sonali</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Bharati Vidyapeeth Medical College &amp; Hospital, Pune, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munshi</LastName><ForeName>Renuka</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>T.N. Medical College &amp; B.Y.L. Nair Charitable Hospital, Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bavdekar</LastName><ForeName>Ashish</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Vadu Rural Health Program KEM Hospital Research Centre Vadu, Pune, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Juvekar</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Vadu Rural Health Program KEM Hospital Research Centre Vadu, Pune, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ganguly</LastName><ForeName>Nupur</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institute of Child Health, Kolkata, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niyogi</LastName><ForeName>Prabal</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Child Health, Kolkata, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uttam</LastName><ForeName>Kheya Ghosh</ForeName><Initials>KG</Initials><AffiliationInfo><Affiliation>Institute of Child Health, Kolkata, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kondekar</LastName><ForeName>Alpana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>T.N. Medical College &amp; B.Y.L. Nair Charitable Hospital, Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumbhar</LastName><ForeName>Dipti</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>T.N. Medical College &amp; B.Y.L. Nair Charitable Hospital, Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohanlal</LastName><ForeName>Smilu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>T.N. Medical College &amp; B.Y.L. Nair Charitable Hospital, Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agarwal</LastName><ForeName>Mukesh C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Seth GS Medical College &amp; KEM Hospital, Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shetty</LastName><ForeName>Parvan</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Seth GS Medical College &amp; KEM Hospital, Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antony</LastName><ForeName>Kalpana</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>PATH, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gunale</LastName><ForeName>Bhagwat</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Serum Institute of India Pvt. Ltd., Pune, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dharmadhikari</LastName><ForeName>Abhijeet</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Serum Institute of India Pvt. Ltd., Pune, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deshpande</LastName><ForeName>Jagdish</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Enterovirus Research Centre, Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nalavade</LastName><ForeName>Uma</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Enterovirus Research Centre, Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Deepa</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Enterovirus Research Centre, Mumbai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bansal</LastName><ForeName>Anurag</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Quest Diagnostics India Private Limited, Gurgaon, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Yuxiao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>PATH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flores</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>PATH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kulkarni</LastName><ForeName>Prasad S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Serum Institute of India Pvt. Ltd., Pune, India. Electronic address: drpsk@seruminstitute.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02584816</AccessionNumber></AccessionNumberList></DataBank><DataBank><DataBankName>CTRI</DataBankName><AccessionNumberList><AccessionNumber>CTRI/2015/07/006034</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>08</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015721">Diphtheria-Tetanus-Pertussis Vaccine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018073">Haemophilus Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017325">Hepatitis B Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C492457">RIX4414 vaccine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022243">Rotavirus Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014613">Vaccines, Attenuated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017778">Vaccines, Combined</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002417" MajorTopicYN="N">Cattle</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015721" MajorTopicYN="N">Diphtheria-Tetanus-Pertussis Vaccine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018073" MajorTopicYN="N">Haemophilus Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017325" MajorTopicYN="N">Hepatitis B Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007115" MajorTopicYN="N">Immunization Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071497" MajorTopicYN="Y">Immunogenicity, Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="N">Poliovirus Vaccine, Inactivated</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016865" MajorTopicYN="N">Reassortant Viruses</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012400" MajorTopicYN="N">Rotavirus Infections</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022243" MajorTopicYN="N">Rotavirus Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014613" MajorTopicYN="N">Vaccines, Attenuated</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017778" MajorTopicYN="N">Vaccines, Combined</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bovine-human reassortant pentavalent rotavirus vaccine (BRV-PV)</Keyword><Keyword MajorTopicYN="N">DTwP-HepB-Hib vaccine</Keyword><Keyword MajorTopicYN="N">Immune response</Keyword><Keyword MajorTopicYN="N">Interference</Keyword><Keyword MajorTopicYN="N">Oral polio vaccine (OPV)</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>4</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>8</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>8</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>9</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30104114</ArticleId><ArticleId IdType="pmc">PMC6143481</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2018.07.064</ArticleId><ArticleId IdType="pii">S0264-410X(18)31073-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tate J.E., Burton A.H., Boschi-Pinto C., Parashar U.D. World Health Organization-coordinated global rotavirus surveillance network. Global, regional, and national estimates of rotavirus mortality in children &lt;5&#x202f;years of age, 2000&#x2013;2013. Clin Infect Dis. 2016;62(Suppl 2):S96&#x2013;S105.</Citation><ArticleIdList><ArticleId IdType="pubmed">27059362</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotavirus vaccines. WHO position paper &#x2013; January 2013.Wkly Epidemiol Rec 2013 February 1; 88(5): p. 49&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">23424730</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunization coverage. Fact sheet. Updated July 2017. http://www.who.int/mediacentre/factsheets/fs378/en/ [accessed 13.09.17].</Citation></Reference><Reference><Citation>Zade J.K., Kulkarni P.S., Desai S.A., Sabale R.N., Naik S.P., Dhere R.M. Bovine rotavirus pentavalent vaccine development in India. Vaccine. 2014;32(Suppl 1):A124&#x2013;A128.</Citation><ArticleIdList><ArticleId IdType="pubmed">25091665</ArticleId></ArticleIdList></Reference><Reference><Citation>Naik S.P., Zade J.K., Sabale R.N., Pisal S.S., Menon R., Bankar S.G. Stability of heat stable, live attenuated Rotavirus vaccine (ROTASIIL&#xae;) Vaccine. 2017;35(22):2962&#x2013;2969.</Citation><ArticleIdList><ArticleId IdType="pubmed">28434688</ArticleId></ArticleIdList></Reference><Reference><Citation>Isanaka S., Guindo O., Langendorf C., MatarSeck A., Plikaytis B.D., Sayinzoga-Makombe N. Efficacy of a low-cost, heat-stable oral rotavirus vaccine in niger. N Engl J Med. 2017;376(12):1121&#x2013;1130.</Citation><ArticleIdList><ArticleId IdType="pubmed">28328346</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulkarni P.S., Desai S., Tewari T., Kawade A., Goyal N., Garg B.S., Kumar D. A randomized Phase III clinical trial to assess the efficacy of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants. Vaccine. 2017;35(45):6228&#x2013;6237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5651219</ArticleId><ArticleId IdType="pubmed">28967523</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical considerations for evaluation of vaccines for prequalification. Points to consider for manufacturers of human vaccines. October 2010. http://www.who.int/immunization_standards/vaccine_quality/clinical_considerations_oct10.pdf [accessed 13.09.17].</Citation></Reference><Reference><Citation>Steele A.D., De Vos B., Tumbo J. Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines. Vaccine. 2010;28(39):6542&#x2013;6548.</Citation><ArticleIdList><ArticleId IdType="pubmed">18786585</ArticleId></ArticleIdList></Reference><Reference><Citation>Vesikari T., Karvonen A., Prymula R. Immunogenicity and safety of the human rotavirus vaccine Rotarix co-administered with routine infant vaccines following the vaccination schedules in Europe. Vaccine. 2010;28(32):5272&#x2013;5279.</Citation><ArticleIdList><ArticleId IdType="pubmed">20538094</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennehy P.H., Bertrand H.R., Silas P.E., Damaso S., Friedland L.R., Abu-Elyazeed R. Coadministration of RIX4414 oral human rotavirus vaccine does not impact the immune response to antigens contained in routine infant vaccines in the United States. Pediatrics. 2008;122(5):e1062&#x2013;e1066.</Citation><ArticleIdList><ArticleId IdType="pubmed">18977955</ArticleId></ArticleIdList></Reference><Reference><Citation>Goveia M.G., Ciarlet M., Owen K.E., Ranucci C.S. Development, clinical evaluation, and post-licensure impact of RotaTeq, a pentavalent rotavirus vaccine. Ann N Y Acad Sci. 2011;1222:14&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">21434938</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel M., Steele A.D., Parashar U.D. Influence of oral polio vaccines on performance of the monovalent and pentavalent rotavirus vaccines. Vaccine. 2012;30(Suppl 1):A30&#x2013;A35.</Citation><ArticleIdList><ArticleId IdType="pubmed">22520134</ArticleId></ArticleIdList></Reference><Reference><Citation>Ing D.J., Glass R.I., Woods P.A., Simonetti M., Pallansch M.A., Wilcox W.D. Immunogenicity of tetravalent rhesus rotavirus vaccine administered with buffer and oral polio vaccine. Am J Dis Child. 1991 Aug;145(8):892&#x2013;897.</Citation><ArticleIdList><ArticleId IdType="pubmed">1650128</ArticleId></ArticleIdList></Reference><Reference><Citation>Emperador D.M., Velasquez D.E., Estivariz C.F., Lopman B., Jiang B., Parashar U. Interference of monovalent, bivalent, and trivalent oral poliovirus vaccines on monovalent rotavirus vaccine immunogenicity in rural Bangladesh. Clin Infect Dis. 2016;62(2):150&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4755336</ArticleId><ArticleId IdType="pubmed">26349548</ArticleId></ArticleIdList></Reference><Reference><Citation>Rennels M.B., Ward R.L., Mack M.E., Zito E.T. Concurrent oral poliovirus and rhesus-human reassortant rotavirus vaccination: effects on immune responses to both vaccines and on efficacy of rotavirus vaccines. The US Rotavirus Vaccine Efficacy Group. J Infect Dis. 1996;173(2):306&#x2013;313.</Citation><ArticleIdList><ArticleId IdType="pubmed">8568290</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaman K., Fleming J.A., Victor J.C., Yunus M., Bari T.I., Azim T.I. Noninterference of rotavirus vaccine with measles-rubella vaccine at 9 months of age and improvements in antirotavirus immunity: a randomized trial. J Infect Dis. 2016;213(11):1686&#x2013;1693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4857472</ArticleId><ArticleId IdType="pubmed">26823338</ArticleId></ArticleIdList></Reference><Reference><Citation>http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000639/WC500054789.pdf [accessed 04.04.18].</Citation></Reference><Reference><Citation>http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000669/WC500054185.pdf [accessed 04.04.18].</Citation></Reference><Reference><Citation>Chandola T.R., Taneja S., Goyal N. ROTAVAC&#xae; does not interfere with the immune response to childhood vaccines in Indian infants: A randomized placebo controlled trial. Heliyon. 2017;3(5)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5435614</ArticleId><ArticleId IdType="pubmed">28560356</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutter R.W., John T.J., Jain H., Agarkhedkar S. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial. Lancet. 2010;376(9753):1682&#x2013;1688.</Citation><ArticleIdList><ArticleId IdType="pubmed">20980048</ArticleId></ArticleIdList></Reference><Reference><Citation>https://mohfw.gov.in/sites/default/files/41016395871489662752.pdf [accessed 20.07.18].</Citation></Reference><Reference><Citation>http://www.who.int/immunization/diseases/poliomyelitis/endgame_objective2/oral_polio_vaccine/OPV-switch-quick-reference-summary-Aug2015.pdf?ua=1 [accessed 11.06.18].</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>